000163837 001__ 163837
000163837 005__ 20240229123157.0
000163837 0247_ $$2doi$$a10.3390/jcm9103107
000163837 0247_ $$2pmid$$apmid:32993054
000163837 037__ $$aDKFZ-2020-02077
000163837 041__ $$aeng
000163837 082__ $$a610
000163837 1001_ $$aArnold, Natalie$$b0
000163837 245__ $$aGrowth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality among Subjects with Osteoarthritis.
000163837 260__ $$aBasel$$bMDPI$$c2020
000163837 3367_ $$2DRIVER$$aarticle
000163837 3367_ $$2DataCite$$aOutput Types/Journal article
000163837 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1601629407_25480
000163837 3367_ $$2BibTeX$$aARTICLE
000163837 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163837 3367_ $$00$$2EndNote$$aJournal Article
000163837 520__ $$aSubjects with osteoarthritis (OA) are at increased risk for cardiovascular (CV) and all-cause mortality. Whether biomarkers improve outcome prediction in these patients remains to be elucidated. We investigated the association between growth differentiation factor 15 (GDF-15), a novel stress-responsive cytokine, and long-term all-cause mortality among OA patients.Within the Ulm Osteoarthritis Study, GDF-15 has been measured in the serum of 636 subjects, who underwent hip or knee arthroplasty between 1995 and 1996 (median age 65 years).During a median follow-up of 19.7 years, a total of 402 deaths occurred. GDF-15 was inversely associated with walking distance. Compared to the bottom quartile (Q), subjects within the top quartile of GDF-15 demonstrated a 2.69-fold increased risk of dying (hazard ratio (HR) (95% confidence interval (CI)) 2.69 (1.82-3.96) adjusted for age, sex, BMI, smoking status, localization of OA, diabetes, maximum walking distance, total cholesterol, and cystatin C. Further adjustment for NT-proBNP, troponin I, and hs-C-reactive protein did not change the results appreciably (HR (95%CI) 1.56 (1.07-2.28); 1.75 (1.21-2.55); 2.32 (1.55-3.47) for Q2, Q3, and Q4 respectively, p for trend < 0.001).In subjects with OA, GDF-15 represents a potent predictor of decreased survival over >20 years, independently of conventional CV risk factors, renal, cardiac, and inflammatory biomarkers as well as walking disability, previously associated with increased mortality and lower extremity OA.
000163837 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000163837 588__ $$aDataset connected to CrossRef, PubMed,
000163837 7001_ $$aRehm, Martin$$b1
000163837 7001_ $$aBüchele, Gisela$$b2
000163837 7001_ $$00000-0003-4310-9500$$aPeter, Raphael Simon$$b3
000163837 7001_ $$aBrenner, Rolf Erwin$$b4
000163837 7001_ $$aGünther, Klaus-Peter$$b5
000163837 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$udkfz
000163837 7001_ $$aKoenig, Wolfgang$$b7
000163837 7001_ $$00000-0002-3563-2791$$aRothenbacher, Dietrich$$b8
000163837 773__ $$0PERI:(DE-600)2662592-1$$a10.3390/jcm9103107$$gVol. 9, no. 10, p. 3107 -$$n10$$p3107 $$tJournal of Clinical Medicine$$v9$$x2077-0383$$y2020
000163837 909CO $$ooai:inrepo02.dkfz.de:163837$$pVDB
000163837 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000163837 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000163837 9141_ $$y2020
000163837 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CLIN MED : 2018$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-01-12
000163837 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CLIN MED : 2018$$d2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2020-01-12
000163837 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-01-12
000163837 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000163837 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000163837 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000163837 980__ $$ajournal
000163837 980__ $$aVDB
000163837 980__ $$aI:(DE-He78)C070-20160331
000163837 980__ $$aI:(DE-He78)C120-20160331
000163837 980__ $$aI:(DE-He78)HD01-20160331
000163837 980__ $$aUNRESTRICTED